Social Media Monitoring on Yescarta: Research and Study on Social Media Channels

Social Media Monitoring Report on Yescarta, a drug by Gilead Sciences, Inc. for relapsed or refractory B-cell lymphoma

Research Study Background

Gilead Sciences, Inc. developed drug Yescarta (axicabtagene ciloleucel) has got US FDA marketing approval on 18^th Oct 2017 for adult patients with relapsed or refractory large B-cell lymphoma. Yescarta US FDA approval was based on data from the ZUMA-1 pivotal trial where Yescarta showed significant improvement with complete response rate by 51 % adult patients with relapsed or refractory large B-cell lymphoma. Yescarta represents the second new advance chemotherapy after Kymriah for adult non-Hodgkin lymphoma patients. Gilead Sciences, Inc. got Prior marketing authorization for Yescarta under Priority Review Scheme by FDA.

1. Study was conducted to understands initial social media reaction where total 1,442 online posts were read by our subject matter experts.
2. Study monitoring period was considered from 5^th October till 25th October 2017.

Findings

1. “HCPs, Patients, News, Advocacy groups and Caregivers sharing information on approval of Yescarta on various Social Media Channels.
2. Twitter followed by Mainstream having maximum volume of conversation.
3. Positive posts were tracked around approval which says- “Yescarta is going to be lifesaving for patients with lymphomas” and
4. HCP reflects on drugs nomiclature and says- “Guinness world record in complex drug name "axicabtagene ciloleucel" defeats tisagenlevleucel! Can we pls use commercial names now!?“

Sentiment Analysis on Yescarta Drug Approval

Positive: Yescarta approval was quoted as a landmark breakthrough - “Yescarta approval is a landmark. Immunotherapy and gene therapy are the most exciting breakthroughs and future of medicine”- Unidentified individual

Negative: Some were found concerned about Yescarta pricing and reflected negatively on social media channels - “Shame..Yescarta List price ($373k) is higher than median home cost in 46 states.”- Unidentified individual

Neutral: Majority of healthcare practitioners were either neutral or positive about the approval and found sharing the information on social media - “FDA approves CAR-T cell therapy (axicabtagene) for adults with R/R DLBCL.“- HCP

Contact us for qualitative social media monitoring and social media intelligence research/reports.